Key facts
- Bernstein reiterates its stock rating for BioNTech.
- Concerns related to pumitamig are cited as the reason for the rating.
Bernstein, an analyst firm, has reiterated its stock rating for BioNTech. The decision to maintain the current rating is based on concerns surrounding the drug pumitamig. The firm has confirmed its existing stance on BioNTech's stock.